Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology

Eitemau Tebyg

• Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology
  gan: Xavier M Teitsma, et al.
  Cyhoeddwyd: (2018-10-01)
• Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy
  gan: Teitsma, Xavier M., et al.
  Cyhoeddwyd: (2017)
• Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab
  gan: Teitsma, Xavier M., et al.
  Cyhoeddwyd: (2020)
• Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate
  gan: Verhoeven, Maxime M A, et al.
  Cyhoeddwyd: (2020)
• Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials
  gan: Teitsma, Xavier M., et al.
  Cyhoeddwyd: (2016)